Advertisement

Oxaliplatin-Induced Neuropathy: Oxidative Stress as Pathological Mechanism. Protective Effect of Silibinin

Published:February 13, 2012DOI:https://doi.org/10.1016/j.jpain.2011.11.009

      Abstract

      Oxaliplatin is the standard treatment for advanced colorectal cancer. Its dose-limiting toxicity is the development of a painful neuropathic syndrome sustained by unclear mechanisms. Although the oxidative hypothesis is a matter of debate, direct data about oxidative damage induced in vivo by anticancer agents are lacking and the efficacy of the available antioxidant compounds are unsatisfactory. In a rat model of painful oxaliplatin-induced neuropathy (2.4 mgkg−1 i.p., daily for 21 days), we described an important component of oxidative stress. In the plasma of oxaliplatin-treated rats, the increases in carbonylated protein and thiobarbituric acid reactive substances were the index of the resultant protein oxidation and lipoperoxidation, respectively. The same pattern of oxidation was revealed also in the sciatic nerve, and in the spinal cord where the damage reached the DNA level. The antioxidant compound silibinin (100 mgkg−1 per os), administered once a day, starting from the first day of oxaliplatin injection until the 20th, prevented oxidative damage as did α-tocopherol. Repetitive administration of silibinin, as well as α-tocopherol, reduced oxaliplatin-dependent pain induced by mechanical and thermal stimuli. Antioxidants were also able to improve motor coordination. The antineuropathic effect of both molecules improved by about 50% oxaliplatin-induced behavioral alterations.

      Perspective

      This study characterizes oxidative stress parameters in a rat model of oxaliplatin-induced neuropathy. A relationship between the improvement of oxidative alterations and pain relief is established in rats treated with natural antioxidant compounds like α-tocopherol and silibinin. Silibinin could be a valid therapeutic option for chemotherapy-induced neuropathy.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The Journal of Pain
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Abenavoli L.
        • Capasso R.
        • Milic N.
        • Capasso F.
        Milk thistle in liver diseases: Past, present, future.
        Phytother Res. 2010; 24: 1423-1432
        • Albers J.W.
        • Chaudry V.
        • Cavaletti G.
        • Donehower R.C.
        Intervention for preventive neuropathy caused by cisplatin and related compound.
        Cochrane Database Syst Rev. 2011; : CD005228
        • Andre T.
        • Bensmaine M.
        • Louvet C.
        • Francois E.
        • Lucas V.
        • Desseigne F.
        • Beerblock K.
        • Bouché O.
        • Carola E.
        • Merrouche Y.
        • Morvan F.
        • Dupont-André G.
        • de Gramont A.
        Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
        J Clin Oncol. 1999; 17: 3560-3568
        • Argyriou A.A.
        • Chroni E.
        • Koutras A.
        • Iconomou G.
        • Papapetropoulos S.
        • Polychronopoulos P.
        • Kalofonos H.P.
        A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: Final results.
        Support Care Cancer. 2006; 14: 1134-1140
        • Beg M.S.
        • Komrokji R.S.
        • Ahmed K.
        • Safa M.M.
        Oxaliplatin-induced immune mediated thrombocytopenia.
        Cancer Chemother Pharmacol. 2008; 62: 925-927
        • Cascinu S.
        • Cordella L.
        • Del Ferro E.
        • Fronzoni M.
        • Catalano G.
        Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial.
        J Clin Oncol. 1995; 13: 26-32
        • Cascinu S.
        • Catalano V.
        • Cordella L.
        • Labianca R.
        • Giordani P.
        • Baldelli A.M.
        • Beretta G.D.
        • Ubiali E.
        • Catalano G.
        Neuroprotective effect of reduced glutathione on oxaliplatinbased chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial.
        J Clin Oncol. 2002; 20: 3478-3483
        • Cavaletti G.
        • Tredici G.
        • Petruccioli M.G.
        • Dondè E.
        • Tredici P.
        • Marmiroli P.
        • Minoia C.
        • Ronchi A.
        • Bayssas M.
        • Erienne G.G.
        Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat.
        Eur J Cancer. 2001; 37: 2457-2463
        • Cersosimo R.J.
        Oxaliplatin-associated neuropathy: A review.
        Ann Pharmacother. 2005; 39: 128-135
        • Cheung C.W.
        • Taylor P.J.
        • Kirkpatrick C.M.
        • Vesey D.A.
        • Gobe G.C.
        • Winterford C.
        • Nicol D.L.
        • Johnson D.W.
        Therapeutic value of orally administered silibinin in renal cell carcinoma: Manipulation of insulin-like growth factor binding protein-3 levels.
        BJU Int. 2007; 100: 438-444
        • Chu S.C.
        • Chiou H.L.
        • Chen P.N.
        • Yang S.F.
        • Hsieh Y.S.
        Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2.
        Mol Carcinogen. 2004; 40: 143-149
        • Díaz-Rubio E.
        • Sastre J.
        • Zaniboni A.
        • Labianca R.
        • Cortés-Funes H.
        • de Braud F.
        • Boni C.
        • Benavides M.
        • Dallavalle G.
        • Homerin M.
        Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study.
        Ann Oncol. 1998; 9: 105-108
        • Disatnik M.
        • Chamberlain J.S.
        • Rando T.A.
        Dystrophin mutations predict cellular susceptibility to oxidative stress.
        Muscle Nerve. 2000; 23: 784-792
        • Extra J.-M.
        • Marty M.
        • Brienza S.
        • Misset J.-L.
        Pharmacokinetics and safety profile of oxaliplatin.
        Semin Oncol. 1998; 25: 13-22
        • Falasca K.
        • Ucciferri C.
        • Mancino P.
        • Vitacolonna E.
        • De Tullio D.
        • Pizzigallo E.
        • Conti P.
        • Vecchiet J.
        Treatment with silybin-vitamin E-phospholipid complex in patients with hepatitis C infection.
        J Med Virol. 2008; 80: 1900-1906
        • Ferrari L.F.
        • Chum A.
        • Bogen O.
        • Reichling D.B.
        • Levine J.D.
        Role of Drp1, a key mitochondrial fission protein, in neuropathic pain.
        J Neurosci. 2011; 31: 11404-11410
        • Gamelin E.
        • Gamelin L.
        • Bossi L.
        • Quasthoff S.
        Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures.
        Semin Oncol. 2002; 29: 21-33
        • Garufi C.
        • Vaglio S.
        • Brienza S.
        • Conti L.
        • D’Attino R.M.
        • Girelli G.
        • Terzoli E.
        Immunohemolytic anemia following oxaliplatin administration.
        Ann Oncol. 2000; 11: 497
      1. Haddad Y, Vallerand D, Brault A, Haddad PS: Antioxidant and Hepatoprotective Effects of Silibinin in a Rat Model of Nonalcoholic Steatohepatitis. Evid Based Complement Alternat Med 2009 Nov 1; [Epub ahead of print]

        • Hammack J.E.
        • Michalak J.C.
        • Loprinzi C.L.
        • Sloan J.A.
        • Novotny P.J.
        • Soori G.S.
        • Tirona M.T.
        • Rowland Jr., K.M.
        • Stella P.J.
        • Johnson J.A.
        Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy.
        Pain. 2002; 98: 195-203
        • Hsieh Y.S.
        • Chu S.C.
        • Yang S.F.
        • Chen P.N.
        • Liu Y.C.
        • Lu K.H.
        Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2.
        Carcinogenesis. 2007; 28: 977-987
        • Jacobs S.S.
        • Fox E.
        • Dennie C.
        • Morgan L.B.
        • McCully C.L.
        • Balis F.M.
        Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
        Clin Cancer Res. 2005; 11: 1669-1674
        • Jacobs S.S.
        • McCully C.L.
        • Murphy R.F.
        • Bacher J.
        • Balis F.M.
        • Fox E.
        Extracellular fluid concentrations of cisplatin, carboplatin and oxaliplatin in brain, muscle and blood measured using microdialysis in nonhuman primates.
        Cancer Chemoter Pharmacol. 2010; 65: 817-824
        • Kaley T.J.
        • Deangelis L.M.
        Therapy of chemotherapy-induced peripheral neuropathy.
        Br J Haematol. 2009; 145: 153
        • Kottschade L.A.
        • Sloan J.A.
        • Mazurczak M.A.
        • Johnson D.B.
        • Murphy B.P.
        • Rowland K.M.
        • Smith D.A.
        • Berg A.R.
        • Stella P.J.
        • Loprinzi C.L.
        The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: Results of a randomized phase III clinical trial.
        Support Care Cancer. 2011; 19: 1769-1777
        • Lah J.J.
        • Cui W.
        • Hu K.O.
        Effects and mechanisms of silibinin on human hepatoma cell lines.
        World J Gastroenterol. 2007; 13: 5299-5305
        • Leighton G.E.
        • Rodriguez R.E.
        • Hill R.G.
        • Hughes J.
        k-opioid agonist produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat.
        Br J Pharmacol. 1988; 93: 553-560
        • Leinonen J.
        • Lehtimäki T.
        • Toyokuni S.
        • Okada K.
        • Tanaka T.
        • Hiai H.
        • Ochi H.
        • Laippala P.
        • Rantalaiho V.
        • Wirta O.
        • Pasternack A.
        • Alho H.
        New biomarker evidence of oxidative DNA damage in patients with non-insulin-dependent diabetes mellitus.
        FEBS Lett. 1997; 417: 150-152
        • Lin P.C.
        • Lee M.Y.
        • Wang W.S.
        • Yen C.C.
        • Chao T.C.
        • Hsiao L.T.
        • Yang M.H.
        • Chen P.M.
        • Lin K.P.
        • Chiou T.J.
        N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data.
        Support Care Cancer. 2006; 14: 484-487
        • Loguercio C.
        • Festi D.
        Silybin and the liver: From basic research to clinical practice.
        World J Gastroenterol. 2011; 17: 2288-2301
        • Lu P.
        • Mamiya T.
        • Lu L.L.
        • Mouri A.
        • Niwa M.
        • Hiramatsu M.
        • Zou L.B.
        • Nagai T.
        • Ikejima T.
        • Nabeshima T.
        Silibinin attenuates amyloid beta25–35 peptide-induced memory impairments: Implication of inducible nitric-oxide synthase and tumor necrosis factor-alpha in mice.
        JPET. 2009; 331: 319-326
        • Muriel P.
        • Moreno M.G.
        • Hernández Mdel C.
        • Chávez E.
        • Alcantar L.K.
        Resolution of liver fibrosis in chronic CCl4 administration in the rat after discontinuation of treatment: Effect of silymarin, silibinin, colchicine and trimethylcolchicinic acid.
        Basic Clin Pharmacol Toxicol. 2005; 96: 375-380
        • National Toxicology Program
        Toxicology and carcinogenesis studies of milk thistle extract (CAS No. 84604-20-6) in F344/N rats and B6C3F1 mice (Feed Studies).
        Natl Toxicol Program Tech Rep Ser. 2011; 565: 1-177
        • Nassini R.
        • Gees M.
        • Harrison S.
        • De Siena G.
        • Materazzi S.
        • Moretto N.
        • Failli P.
        • Preti D.
        • Marchetti N.
        • Cavazzini A.
        • Mancini F.
        • Pedretti P.
        • Nilius B.
        • Patacchini R.
        • Geppetti P.
        Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation.
        Pain. 2011; 152: 1621-1631
        • Pace A.
        • Savarese A.
        • Picardo M.
        • Maresca V.
        • Pacetti U.
        • Del Monte G.
        • Biroccio A.
        • Leonetti C.
        • Jandolo B.
        • Cognetti F.
        • Bove L.
        Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy.
        J Clin Oncol. 2003; 21: 927-931
        • Pan H.
        • Mukhopadhyay P.
        • Rajesh V.
        • Mukhopadhyay B.
        • Gao B.
        • Hasko G.
        • Pacher P.
        Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death.
        J Pharm Exp Ther. 2009; 3: 708-714
        • Park S.A.
        • Choi K.S.
        • Bang J.H.
        • Huh K.
        • Kim S.U.
        Cisplatin-induced apoptotic cell death in mouse hybrid neurons is blocked by antioxidants through suppression of cisplatin-mediated accumulation of p53 but not of Fas/Fas ligand.
        J Neurochem. 2000; 75: 946-953
        • Penz M.
        • Kornek G.V.
        • Raderer M.
        • Ulrich-Pur H.
        • Fiebiger W.
        • Scheithauer W.
        Subcutaneous administration of amifostine: A promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy.
        Ann Oncol. 2001; 12: 421-422
        • Post-White J.
        • Ladas E.J.
        • Kelly K.M.
        Advances in the use of milk thistle (Silybum marianum).
        Integr Cancer Ther. 2007; 6: 104-109
        • Provinciali M.
        • Papalini F.
        • Orlando F.
        • Pierpaoli S.
        • Donnini A.
        • Morazzoni P.
        • Riva A.
        • Smorlesi A.
        Effect of the silybin phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice.
        Cancer Res. 2007; 67: 2022-2029
        • Ramasamy K.
        • Agarwal R.
        Multitargeted therapy of cancer by silymarin.
        Cancer Lett. 2008; 269: 352-362
        • Rothenberg M.L.
        • Oza A.M.
        • Bigelow R.H.
        • Berlin J.D.
        • Marshall J.L.
        • Ramanathan R.K.
        • Hart L.L.
        • Gupta S.
        • Garay C.A.
        • Burger B.G.
        • Le Bail N.
        • Haller D.G.
        Superiority of oxaliplatin and fluorouracil leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial.
        J Clin Oncol. 2003; 21: 2059-2069
        • Sakurai M.
        • Egashira N.
        • Kawashiri T.
        • Yano T.
        • Ikesue H.
        • Oishi R.
        Oxaliplatin-induced neuropathy in the rat: Involvement of oxalate in cold hyperalgesia but not mechanical allodynia.
        Pain. 2009; 147: 165-174
        • Saller R.
        • Meier R.
        • Brignoli R.
        The use of silymarin in the treatment of liver diseases.
        Drugs. 2001; 61: 2035-2063
        • Shen J.
        • Deininger P.
        • Hunt J.D.
        • Zhao H.
        8-Hydroxy-2’-deoxyguanosine (8-OH-dG) as a potential survival biomarker in patients with nonsmall-cell lung cancer.
        Cancer. 2007; 109: 574-580
        • Singh R.P.
        • Agarwal R.
        Prostate cancer chemoprevention by silibinin: Bench to bedside.
        Mol Carcinogen. 2006; 45: 436-442
        • Ta L.E.
        • Espeset L.
        • Podratz J.
        • Windebank A.J.
        Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding.
        Neurotoxicology. 2006; 27: 992-1002
        • Taleghani B.M.
        • Meyer O.
        • Fontana S.
        • Ahrens N.
        • Novak U.
        • Borner M.M.
        • Salama A.
        Oxaliplatin-induced immune pancytopenia.
        Transfusion. 2005; 8: 704-708
        • Tomé A.R.
        • Feng D.
        • Freitas R.M.
        The effects of alpha-tocopherol on hippocampal oxidative stress prior to in pilocarpine-induced seizures.
        Neurochem Res. 2010; 35: 580-587
        • Vigueras-Villaseñor R.M.
        • Ojeda I.
        • Gutierrez-Pérez O.
        • Chavez-Saldaña M.
        • Cuevas O.
        • Maria D.S.
        • Rojas-Castañeda J.C.
        Protective effect of α-tocopherol on damage to rat testes by experimental cryptorchidism.
        Int J Exp Pathol. 2011; 92: 131-139
        • Zheng H.
        • Xiao W.H.
        • Bennett G.J.
        Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy.
        Exp Neurol. 2011; 232: 154-161